Abstract
An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.
Full text
PDF

Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- KURTZKE J. F. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955 Aug;5(8):580–583. doi: 10.1212/wnl.5.8.580. [DOI] [PubMed] [Google Scholar]
- Neumann J. W., Ziegler D. K. Therapeutic trial of immunosuppressive agents in multiple sclerosis. Neurology. 1972 Dec;22(12):1268–1271. doi: 10.1212/wnl.22.12.1268. [DOI] [PubMed] [Google Scholar]